Inactive Instrument

SANOCHEMIA Pharmazeutika AG Stock price Wiener Boerse

Equities

SCPH

AT0000776307

Pharmaceuticals

Dynamic Chart
EOSS Technology GmbH, Wirtschaft Burgenland GmbH – WiBuG and b·e·imaging·GmbH acquired SANOCHEMIA Pharmazeutika AG from bew Beteiligungs GmbH and other shareholders. CI
SANOCHEMIA Pharmazeutika AG announced that it has received €6 million in funding from bew Beteiligungs GmbH CI
Bew Beteiligungs GmbH acquired an unknown stake in SANOCHEMIA Pharmazeutika AG from Inphasearch AG. CI
SANOCHEMIA Pharmazeutika AG announced that it expects to receive €6 million in funding from bew Beteiligungs GmbH CI
SANOCHEMIA Pharmazeutika AG Announces Positive Topline Results from Phase 2 Star Study of Tolperisone in Acute Muscle Spasms of the Back in the U.S CI
Sanochemia Pharmazeutika Ag Names Timo Bender as CEO, Effective February 1, 2019 CI
B·e·imaging·GmbH acquired 14.5% stake in SANOCHEMIA Pharmazeutika AG from Inphasearch AG. CI
SANOCHEMIA Pharmazeutika AG Announces Board Changes CI
Sanochemia Pharmazeutika Ag Reports Earnings Results for the Six Months of the Year 2018 CI
Sanochemia Pharmazeutika AG Announces Sales Results for the First Quarter of Fiscal 2017; Provides Earnings Guidance for the Full Year of Fiscal 2017 CI
Invesa AG and Inphasearch AG cancelled the acquisition of 34.9% stake in Sanochemia Pharmazeutika AG from Sanochemia Ltd. CI
Sanochemia Announces Earnings Results for the Full Year of Fiscal 2016 CI
Invesa AG and Inphasearch AG agreed to acquire 34.9% stake in Sanochemia Pharmazeutika AG from Sanochemia Ltd. CI
Sanochemia Extends Contracts with Janssen N.V CI
Sanochemia Reports Preliminary Earnings Results for the Fiscal Year 2013 CI
More news
Managers TitleAgeSince
Chief Executive Officer 50 -
Chief Executive Officer 47 -
Founder 77 90-11-12
Members of the board TitleAgeSince
Founder 77 90-11-12
Director/Board Member 76 98-09-27
Director/Board Member - -
More insiders
Sanochemia Pharmazeutika AG is an Austrian pharmaceutical company focused on the development and manufacture of drugs and diagnostics in neurodegeneration, pain and oncology areas, among others, as well as diagnostics based on contrast media. It operates through three main business divisions and the Production Division, which acts on behalf of those business divisions or on a contract manufacturing basis. The Production Division is engaged in the synthesis of active pharmaceutical substances (APIs), drug formulation and pharmaceutical production. The Human Pharmaceuticals Division is primarily responsible for the Company's diagnostic activities. The Research and Development Division is responsible for the Company's development activities. The Veterinary Pharmaceuticals Division comprises a portfolio of veterinary medical product and distribution channels in the CEE markets, Middle East and South-East Asia. The Company's shareholders are Inphasearch AG and Invesa AG, among others.
More about the company
  1. Stock
  2. Equities
  3. Stock SANOCHEMIA Pharmazeutika AG
  4. Stock SANOCHEMIA Pharmazeutika AG - Wiener Boerse